Relmada Therapeutics Inc. (US75955J4022)
XSTU 
Summary
US75955J4022 Chart
Relmada Therapeutics Q1 Earnings Call Highlights
Relmada Therapeutics NASDAQ: RLMD said it remains on track to begin its Phase 3 RESCUE registrational program for NDV-01 in mid-2026 after reporting 12-month Phase 2 data in non-muscle invasive bladder cancer and strengthening its balance sheet through a private financing.
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Relmada Therapeutics, Inc. (RLMD) Q1 2026 Earnings Call Transcript
Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?
The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Relmada Therapeutics Inc. (US75955J4022) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Relmada Therapeutics Inc. ever had a stock split?
Relmada Therapeutics Inc. Profile
| Biotechnology Industry | Healthcare Sector | Sergio Traversa CEO | XSTU Exchange | US75955J4022 ISIN |
| US Country | 17 Employees | 30 Sep 2019 Last Dividend | 30 Sep 2019 Last Split | 9 Oct 2014 IPO Date |
Overview
Relmada Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating treatments for central nervous system (CNS) diseases and other disorders. Established in 2004 and based in Coral Gables, Florida, the company is at the forefront of researching and producing innovative therapies that address a variety of mental and neurological conditions. Their approach combines cutting-edge science with a deep understanding of patient needs to develop new therapeutic options for diseases that are currently difficult to treat.
Products and Services
- Esmethadone (d-methadone, dextromethadone, and REL-1017): This lead product candidate represents a major innovation in the treatment of central nervous system disorders. As a new chemical entity, Esmethadone acts as an N-methyl-D-aspartate receptor antagonist. Currently, it is under Phase 3 clinical trials specifically designed to evaluate its efficacy as an adjunctive or monotherapy in the treatment of major depressive disorder in adults. This focus on a key area of unmet medical need, major depressive disorder, highlights Relmada Therapeutics' commitment to addressing the challenges within the realm of mental health treatment through advanced scientific research.
